ReviewTherapeutics and clinical risk management2026
The Therapeutic Role of Biologics in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): A Review of the Current Evidence.
Review in Therapeutics and clinical risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex inflammatory condition that is primarily categorized as either Type 2 (T2) or non-T2. The T2 inflammatory pathway plays a pivotal role in the pathogenesis of T2 CRSwNP. A significant proportion of patients do not respond to systemic glucocorticoid regimens or repeated surgical interventions, which severely impacts their long-term quality of life and presents a therapeutic challenge. Recent studies confirm that biologics are an effective treatment for severe or refractory CRSwNP. This review systematically collates the latest advances in biological therapies for CRSwNP by conducting extensive searches of the PubMed, Embase, and Cochrane Library databases from the inception of these databases up to October 2025. The review focuses on elucidating the pathological mechanisms of CRSwNP and the classification and target mechanisms of biologics. It also examines the current research landscape regarding variability in biologics efficacy. Substantial clinical evidence indicates that these biologics can effectively alleviate symptoms of sinusitis, reduce turbinate volume, and improve patients' quality of life. They also demonstrate potential in improving comorbid conditions, offering novel therapeutic options for severe or refractory CRSwNP. However, challenges remain in identifying biomarkers and selecting suitable biologics, requiring further research to enable personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.